Poly-CD-PEG-camptothecin Combined with Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (Clinical trial)
The authors hypothesized that integrating tumor-targeted topoisomerase I inhibitor delivery with optimized PARP inhibitor scheduling could enable effective combination therapy